PSTV
Plus Therapeutics, Inc. [PSTV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PSTV Stock Summary
Top 10 Correlated ETFs
PSTV
Top 10 Correlated Stocks
PSTV
In the News
Penny Stocks To Buy Now? 4 To Watch Before Next Week
Penny stocks, also known as micro-cap equities or stocks under $5 per share, offer investors affordable opportunities. This is to buy shares in emerging small companies early before potential growth and upside.
Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Chief Medical Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon, ladies and gentlemen.
Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2023 financial results on Tuesday, October 31, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will present data from its ReSPECT-LM clinical trial evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of leptomeningeal metastases at the Cancer Prevention & Research Institute of Texas (CPRIT) Innovations in Cancer Prevention and Research Conference VI. The conference is taking place October 2-3, 2023, in Galveston, Tex. The poster presentation is titled, Report of Phase 1 Part A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM) .
Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 3:00 p.m. ET at the Lotte New York Palace in New York, NY.
Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capita Operator Good afternoon, ladies and gentlemen.
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2023 financial results on Monday, August 14, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the Canaccord Genuity 43rd Annual Growth Conference, on Wednesday, August 9, 2023 at 8:00 a.m. ET at the InterContinental Boston in Boston, Mass.
Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer, will give two presentations at the Targeted Radiopharmaceuticals Summit taking place July 25-27, 2023 in Boston, Massachusetts.
PSTV Financial details
PSTV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 257.38 | 75.85 | 1.03 | 0 | 0.13 | |
| Net income per share | -1.09K | -138.1 | -31.67 | -17.78 | -11.91 | |
| Operating cash flow per share | -1.03K | -64.01 | -28.57 | -12.76 | -7.41 | |
| Free cash flow per share | -1.04K | -64.74 | -30.24 | -12.93 | -7.7 | |
| Cash per share | 453.93 | 190.23 | 28.27 | 22.83 | 10.35 | |
| Book value per share | 450.82 | 12.57 | 10.27 | 13.45 | 3.68 | |
| Tangible book value per share | -95.25 | 8.54 | 8.72 | 12.92 | 3.42 | |
| Share holders equity per share | 450.82 | 12.57 | 10.27 | 13.45 | 3.68 | |
| Interest debt per share | 1.39K | 148.57 | 27.45 | 9.83 | 3.63 | |
| Market cap | 2.52M | 3.32M | 8.94M | 12.69M | 8.4M | |
| Enterprise value | 11.46M | -2.38M | 7.59M | 1.29M | -4.07M | |
| P/E ratio | -0.2 | -0.26 | -0.96 | -0.89 | -0.4 | |
| Price to sales ratio | 0.85 | 0.47 | 29.52 | 0 | 37.51 | |
| POCF ratio | -0.21 | -0.56 | -1.06 | -1.23 | -0.65 | |
| PFCF ratio | -0.21 | -0.56 | -1 | -1.22 | -0.62 | |
| P/B Ratio | 0.48 | 2.86 | 2.95 | 1.17 | 1.3 | |
| PTB ratio | 0.48 | 2.86 | 2.95 | 1.17 | 1.3 | |
| EV to sales | 3.84 | -0.34 | 25.06 | 0 | -18.18 | |
| Enterprise value over EBITDA | -1.71 | 0.88 | -0.83 | -0.11 | 0.21 | |
| EV to operating cash flow | -0.96 | 0.4 | -0.9 | -0.13 | 0.31 | |
| EV to free cash flow | -0.95 | 0.4 | -0.85 | -0.12 | 0.3 | |
| Earnings yield | -5.01 | -3.84 | -1.05 | -1.13 | -2.48 | |
| Free cash flow yield | -4.8 | -1.8 | -1 | -0.82 | -1.6 | |
| Debt to equity | 2.72 | 10.22 | 2.31 | 0.65 | 0.88 | |
| Debt to assets | 0.59 | 0.51 | 0.58 | 0.32 | 0.24 | |
| Net debt to EBITDA | -1.33 | 2.11 | 0.15 | 0.95 | 0.66 | |
| Current ratio | 0.55 | 1.37 | 1.07 | 3.36 | 1.84 | |
| Interest coverage | -4.56 | -1.97 | -8.66 | -13.4 | -27.72 | |
| Income quality | 0.95 | 0.54 | 1.02 | 0.77 | 0.64 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.87 | 0.69 | 21.14 | 0 | 45.71 | |
| Research and developement to revenue | 1.85 | 0.77 | 11.49 | 0 | 43.29 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.04 | 0.02 | 0.02 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0.06 | 0.01 | 0.04 | |
| Capex to revenue | -0.04 | -0.01 | -1.63 | 0 | -2.27 | |
| Capex to depreciation | -0.07 | -0.07 | -1.35 | -0.36 | -0.82 | |
| Stock based compensation to revenue | 0.12 | 0.02 | 0.82 | 0 | 2.71 | |
| Graham number | 3.33K | 197.65 | 85.53 | 73.34 | 31.41 | |
| ROIC | -0.55 | -1.03 | -1.02 | -0.73 | -1.64 | |
| Return on tangible assets | -0.53 | -0.56 | -0.8 | -0.66 | -0.89 | |
| Graham Net | -1.15K | -38.87 | -2.32 | 9 | 0.4 | |
| Working capital | -7.91M | 5.34M | 636K | 13.85M | 9.97M | |
| Tangible asset value | 4.85M | 788K | 2.57M | 10.41M | 5.98M | |
| Net current asset value | -9.12M | -2.24M | 101K | 8.58M | 4.4M | |
| Invested capital | 2.72 | 10.22 | 2.31 | 0.65 | 0.88 | |
| Average receivables | 189K | 701K | 614K | 33K | 3.5K | |
| Average payables | 1.01M | 524K | 558K | 1.7M | 5.49M | |
| Average inventory | 1.65M | 107K | 53.5K | -3.5K | -3.5K | |
| Days sales outstanding | 28.51 | 60.97 | 71.07 | 0 | 0 | |
| Days payables outstanding | 229.24 | 0 | 0 | 14.44K | 0 | |
| Days of inventory on hand | 34.02 | 0 | 0 | -38.71 | 0 | |
| Receivables turnover | 12.8 | 5.99 | 5.14 | 0 | 0 | |
| Payables turnover | 1.59 | 0 | 0 | 0.03 | 0 | |
| Inventory turnover | 10.73 | 0 | 0 | -9.43 | 0 | |
| ROE | -2.42 | -10.98 | -3.08 | -1.32 | -3.23 | |
| Capex per share | -11.48 | -0.73 | -1.67 | -0.18 | -0.29 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.1 | 0 | 0.74 | 0 | |
| Net income per share | -2.92 | -2.56 | -2.07 | -0.59 | -1 | |
| Operating cash flow per share | -2.31 | -1 | -2.5 | -1.11 | -0.74 | |
| Free cash flow per share | -2.33 | -1 | -2.54 | -1.11 | -0.75 | |
| Cash per share | 11.08 | 8.08 | 5.48 | 4.34 | 3.41 | |
| Book value per share | 6.23 | 2.87 | 1.15 | 1.06 | 0.81 | |
| Tangible book value per share | 5.97 | 2.66 | 0.96 | 0.89 | 0.68 | |
| Share holders equity per share | 6.23 | 2.87 | 1.15 | 1.06 | 0.81 | |
| Interest debt per share | 3.37 | 2.59 | 2.36 | 2.02 | 1.45 | |
| Market cap | 12.35M | 10.77M | 10.09M | 5.07M | 4.32M | |
| Enterprise value | -1.92M | -1.71M | 2.7M | -871.06K | -2.1M | |
| P/E ratio | -0.58 | -0.47 | -0.52 | -0.86 | -0.34 | |
| Price to sales ratio | 0 | 48.08 | 0 | 2.73 | 0 | |
| POCF ratio | -2.92 | -4.82 | -1.74 | -1.82 | -1.8 | |
| PFCF ratio | -2.9 | -4.8 | -1.71 | -1.82 | -1.79 | |
| P/B Ratio | 1.08 | 1.67 | 3.77 | 1.9 | 1.65 | |
| PTB ratio | 1.08 | 1.67 | 3.77 | 1.9 | 1.65 | |
| EV to sales | 0 | -7.62 | 0 | -0.47 | 0 | |
| Enterprise value over EBITDA | 0.39 | 0.32 | -0.6 | 0.7 | 0.73 | |
| EV to operating cash flow | 0.46 | 0.76 | -0.47 | 0.31 | 0.88 | |
| EV to free cash flow | 0.45 | 0.76 | -0.46 | 0.31 | 0.87 | |
| Earnings yield | -0.43 | -0.53 | -0.48 | -0.29 | -0.74 | |
| Free cash flow yield | -0.34 | -0.21 | -0.58 | -0.55 | -0.56 | |
| Debt to equity | 0.53 | 0.88 | 1.99 | 1.86 | 1.75 | |
| Debt to assets | 0.26 | 0.24 | 0.34 | 0.35 | 0.35 | |
| Net debt to EBITDA | 2.92 | 2.34 | 1.65 | 4.79 | 2.22 | |
| Current ratio | 2.81 | 1.84 | 1.07 | 1.08 | 1.1 | |
| Interest coverage | -29.45 | -35.04 | -35.22 | -13.3 | -37.37 | |
| Income quality | 0.81 | 0.39 | 1.21 | 1.87 | 0.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 16 | 0 | 1.04 | 0 | |
| Research and developement to revenue | 0 | 9.54 | 0 | 0.77 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | 0.01 | 0 | 0.02 | 0 | 0 | |
| Capex to revenue | 0 | -0.05 | 0 | -0.01 | 0 | |
| Capex to depreciation | -0.21 | -0.07 | -0.52 | -0.08 | -0.04 | |
| Stock based compensation to revenue | 0 | 0.58 | 0 | 0.08 | 0 | |
| Graham number | 20.24 | 12.86 | 7.33 | 3.75 | 4.27 | |
| ROIC | -0.3 | -0.46 | -0.57 | -0.2 | -0.45 | |
| Return on tangible assets | -0.24 | -0.25 | -0.32 | -0.11 | -0.25 | |
| Graham Net | 4.71 | 0.31 | -0.1 | -0.04 | 0.13 | |
| Working capital | 13.46M | 9.97M | 833K | 965K | 1.05M | |
| Tangible asset value | 10.92M | 5.98M | 2.23M | 2.23M | 2.2M | |
| Net current asset value | 9.18M | 4.4M | 667K | 829K | 928K | |
| Invested capital | 0.53 | 0.88 | 1.99 | 1.86 | 1.75 | |
| Average receivables | 36.5K | 36.5K | 0 | 359K | 404.5K | |
| Average payables | 5.48M | 7.03M | 7.43M | 3.25M | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 34.85 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 2.58 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.47 | -0.89 | -1.8 | -0.56 | -1.23 | |
| Capex per share | -0.02 | 0 | -0.04 | 0 | 0 |
PSTV Frequently Asked Questions
What is Plus Therapeutics, Inc. stock symbol ?
Plus Therapeutics, Inc. is a US stock , located in Austin of Tx and trading under the symbol PSTV
What is Plus Therapeutics, Inc. stock quote today ?
Plus Therapeutics, Inc. stock price is $2.12 today.
Is Plus Therapeutics, Inc. stock public?
Yes, Plus Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 612.86K
- Market Capitalization 9.59M
- Employee 17
- CEO Dr. Marc H. Hedrick M.B.A., M.D.
- Headquarters Austin,TX,US
- IPO Date 2001-07-11
-
Website
https://www.plustherapeutics.com 
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
